Don’t Try ARBs for Severe COVID, Trial Indicates

MedPage Today) — The angiotensin receptor blocker (ARB) losartan led to hypotension and failed to improve mortality in patients hospitalized for acute COVID-19, according to the randomized, prospective — and prematurely terminated — ARBs…